Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

804.62 -16.57 (-2.02%)
Official Closing Price Updated: 7:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,173,976
Open 811.87
Bid (Size) 802.16 (1)
Ask (Size) 804.61 (1)
Prev. Close 821.19
Today's Range 801.30 - 822.01
52wk Range 446.89 - 966.10
Shares Outstanding N/A
Dividend Yield 0.56%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyzing Eli Lilly and Co In Comparison To Competitors In Pharmaceuticals Industry
Via Benzinga
Stock Market Diverges, With Tesla, Google, ServiceNow, GE In Focus: Weekly Review
Small caps continued to lead, while the Nasdaq broke below key levels. 
Via Investor's Business Daily

Performance

YTD
+35.87%
+35.87%
1 Month
-10.72%
-10.72%
3 Month
+9.69%
+9.69%
6 Month
+25.87%
+25.87%
1 Year
+76.84%
+76.84%

More News

Read More
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
Via Benzinga
Expert Outlook: Eli Lilly and Co Through The Eyes Of 25 Analysts
Via Benzinga
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
Via Investor's Business Daily
Prediction: This Is What Eli Lilly Stock Will Do Next
Via The Motley Fool
Walt Disney, Eli Lilly, AST SpaceMobile, DexCom, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
Via The Motley Fool
7 Explosive Growth Stocks Set to Soar in 2024
Via InvestorPlace
Novo Nordisk Shares Decline Amid Competitive Pressure
Via Benzinga
3 Top-Performing Stocks Beating the Big Names in 2024
Via InvestorPlace
Viking Therapeutics Stock Surges As Company Advances Weight Loss Drug To Late-Stage Trial: What Investors Need To Know
Via Benzinga
Why Eli Lilly and Company Shares Are Moving Lower On Thursday
Via Benzinga
3 Companies Gearing Up for a Stock Split
Via InvestorPlace
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years
Via Benzinga
Viking Therapeutics Unveils Monthly Weight-Loss Shot, And Rocks Eli Lilly, Novo Nordisk
Via Investor's Business Daily
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
Via FinancialNewsMedia
Exposures Product Safety
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
From FN Media Group LLC
Via GlobeNewswire
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
Via InvestorPlace
Elon Musk Agrees With Former Executive Who Thinks 'Everyone' Has 'Strong' Opinions On Tesla Unlike In The Case Of Eli Lilly And LVMH
Via Benzinga
3 Fabulous Growth Stocks to Buy and Hold Forever
Via InvestorPlace
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Via Benzinga
3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years
Via The Motley Fool
If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.